YHLO

iFlash-2019-nCoV NAb (Neutralization Antibody) assay is a chemiluminescence immunoassay (CLIA) for the qualitative determination of 2019-nCoV Neutralization Antibodies in human serum or plasma.

Clinical Benefits:

Evaluate COVID-19 vaccines development and efficacy
Monitor the NAb titers in COVID-19 patients and vaccinated individuals.
Analyze herd immunity status to guide policymakers.
Monitoring in during convalescent plasma therapy or other antibody related treatments.

Download the IFU（German Version）：

GLINE-2019-nCoV Antigen Saliva Rapid Test

GLINE-2019-nCoV Rapid Antigen Test

Home

About YHLO

Products

Services

News

Company Profile Milestone Corporate Values

About YHLO

YHLO (EST. 2008) is an innovative and steadfastly growing company of immunoassay solutions headquartered in Shenzhen, China, specialized in developing, manufacturing and distributing in-vitro diagnostic instruments and reagents by a team of experienced scientists and engineers. In May of 2021, YHLO has successfully launched IPO and listed on Shanghai Stock Exchange (Stock code: 688575).

More +

Clinical Solution CLIA ELISA LIA ESR COVID-19

Products

Based on the technology platforms of CLIA, ELISA, LIA and immunofluorescence, YHLO is specialized in diagnosis of autoimmunity, reproductive health, diabetes, infectious diseases etc.

More +